natgillin/translations-raw huggingface dataset:
In particular, you should ask your doctor if you want to use a medicine containing domperidone for the treatment of nausea and/or vomiting.
Še zlasti se posvetujte z zdravnikom, če želite jemati zdravilo proti slabosti in/ali bruhanju, ki vsebuje domperidon.
In particular, you should be cautious if you take Wakix together with some antidepressants (e.g. imipramine, clomipramine and mirtazapine) and some medicines to treat allergic conditions (anti- histamines, e.g. pheniramine maleate, chlorpheniramine, diphenydramine, promethazine, mepyramine).
Še posebej previdni morate biti, če zdravilo Wakix jemljete sočasno z določenimi antidepresivi (npr. z imipraminom, klomipraminom in mirtazapinom) ter določenimi zdravili za zdravljenje alergij (antihistaminiki, kot so feniraminijev maleat, klorfeniramin, difenidramin, prometazin in mepiramin).
In particular, you should not be given MabCampath within 3 weeks of taking any other anti-cancer agents.
Zlasti pomembno je, da zdravila MabCampath ne dobite manj kot 3 tedne pred oz. po drugih zdravilih proti raku.
In particular, you should tell your doctor if you are taking medicines containing any of the following active substances:
Zdravnika morate obvestiti zlasti, če jemljete zdravila, ki vsebujejo katero od naslednjih zdravilnih učinkovin:
In particular, you should tell your doctor if you are using the following medicines including those containing any of the active substances listed below: carbamazepine, phenobarbital or phenytoin.
Še zlasti obvestite svojega zdravnika, če uporabljate zdravila, ki vsebujejo katero od naslednjih naštetih zdravilnih učinkovin:
In particular, your doctor may need to adjust your Briviact dose if you take the following medicines:
Še posebno zato, ker vam bo morda zdravnik moral prilagoditi odmerek zdravila Briviact, če jemljete naslednja zdravila:
In particular, your doctor will consider vaccinating you against chickenpox if you have never had it.
Predvsem se bo osredotočil na cepljenje proti noricam (vodenim kozam), če jih še niste imeli.
In PATENT-2, all patients received an individualised riociguat dose up to 2.5 mg three times daily.
V študiji PATENT-2 so vsi bolniki prejemali bolniku prilagojen odmerek riociguata do največ 2,5 mg trikrat na dan.
In patients (n = 39) with recurrence within 180 days after chemoradiotherapy with cisplatin, the median survival in the topotecan plus cisplatin arm was 4.6 months (95 % C.I.: 2.6, 6.1) versus
Pri bolnicah (n = 39) s ponovitvijo v 180 dneh po kemoradioterapiji s cisplatinom je bila mediana vrednost preživetja v skupini, ki je prejemala topotekan in cisplatin, 4,6 meseca (95 % interval zaupanja: 2,6; 6,1), v skupini, ki je prejemala cisplatin, pa 4,5 meseca (95 % intervala zaupanja: 2,9; 9,6), razmerje tveganja 1,15 (0,59; 2,23).
In patients (n = 39) with recurrence within 180 days after chemoradiotherapy with cisplatin, the median survival in the topotecan plus cisplatin arm was 4.6 months (95 % C.I.: 2.6, 6.1) versus
Pri bolnicah (n = 39) s ponovitvijo v 180 dneh po kemoradioterapiji s cisplatinom je bila mediana vrednost preživetja v skupini, ki je prejemala topotekan in cisplatin, 4,6 meseca (95% interval zaupanja: 2,6; 6,1), v skupini, ki je prejemala cisplatin, pa 4,5 meseca (95% intervala zaupanja: 2,9;
In patients (n=20) from clinical studies with increases in ALT to more than 5 times the ULN, treatment was discontinued and the levels returned to less than 2 times the ULN within 2 to 4 months in most cases (see section 4.4)
Pri bolnikih (n=20), sodelujočih v kliničnih študijah, z zvišano ALT več kot 5 kratno ULN je bilo zdravljenje prekinjeno in v večini primerov so se koncentracije znižale na manj kot 2 kratno ULN v 2 do 4 mesecih (glejte poglavje 4.4).
In patients (n=20) from clinical studies with increases in ALT to more than 5 times the ULN, treatment was discontinued and the levels returned to less than 2 times the ULN within 2 to 4 months in most cases (see section 4.4).
Pri bolnikih (n=20), sodelujočih v kliničnih študijah, z zvišano ALT več kot 5 kratno ULN je bilo zdravljenje prekinjeno in v večini primerov so se koncentracije znižale na manj kot 2 kratno ULN v 2 do 4 mesecih. (glejte poglavje 4.4)
In patients (n=39) with recurrence within 180 days after chemoradiotherapy with cisplatin, the median survival in the topotecan plus cisplatin arm was 4.6 months (95 % C.I.: 2.6, 6.1) versus 4.5 months (95 %C.I.: 2.9, 9.6) for the cisplatin arm with an hazard ratio of 1.15 (0.59, 2.23).
Pri bolnicah (n = 39) s ponovitvijo v 180 dneh po kemoradioterapiji s cisplatinom je bila mediana vrednost preživetja v skupini, ki je prejemala topotekan in cisplatin, 4,6 meseca (95 % interval zaupanja: 2,6; 6,1), v skupini, ki je prejemala cisplatin, pa 4,5 meseca (95 % intervala zaupanja: 2,9; 9,6), razmerje tveganja 1,15 (0,59; 2,23).
In patients (n=39) with recurrence within 180 days after chemoradiotherapy with cisplatin, the median survival in the topotecan plus cisplatin arm was 4.6 months (95% C.I.: 2.6, 6.1) versus 4.5 months (95% C.I.: 2.9, 9.6) for the cisplatin arm with an hazard ratio of 1.15 (0.59, 2.23).
Pri bolnicah (n = 39) s ponovnim pojavom bolezni v času 180 dni po kemoradioterapiji s cisplatinom je bila mediana vrednost preživetja v kraku oz. skupini, ki je prejemala topotekan in cisplatin, 4,6 meseca (95 % IZ: 2,6; 6,1), v primerjavi s 4,5 meseca (95 % IZ: 2,9; 9,6) za krak oz. skupino, ki je prejemala cisplatin, razmerje tveganj pa je bilo 1,15 (0,59; 2,23).
in patients (particularly overweight patients) inadequately controlled by diet and exercise for
pri bolnikih (še posebej bolnikih s prekomerno telesno maso), ki z dieto in telesno vadbo niso
In patients 3 years of age or older, TMZ is only to be used in recurrent or progressive malignant glioma.
Pri bolnikih starih 3 leta ali več, se TMZ sme uporabljati samo za zdravljenje ponavljajočega se ali napredujočega malignega glioma.
In patients 3 years of age or older, TMZ is only to be used in recurrent or progressive malignant glioma.
Pri bolnikih, starih 3 leta ali več, se TMZ uporablja le pri ponovljenem ali napredovalem malignem gliomu. .
In patients >75 years undergoing orthopaedic surgery and receiving fondaparinux 2.5 mg once daily, the estimated plasma clearance was 1.2 to 1.4 times lower than in patients <65 years.
Pri bolnikih, > 75 let, ki so imeli ortopedsko operacijo in so dobivali fondaparinuks v odmerku 2,5 mg enkrat na dan, je ocenjeni očistek plazme 1,2 do 1,4- krat manjši kot pri bolnikih, < 65 let.
In patients >75 years undergoing orthopaedic surgery, the estimated plasma clearance was 1.2 to 1.4 times lower than in patients <65 years.
Pri bolnikih, > 75 let, z ortopedskimi operacijami, je ocenjeni očistek plazme 1,2 do 1,4-krat manjši kot pri bolnikih, < 65 let.
in patients above 60 years of age
pri bolnikih, starejših od 60 let
In patients above 60 years, therapy should start with a dose of 0.1 - 0.2 mg per day and should be slowly increased according to individual patient requirements.
Pri bolnikih, starih več kot 60 let, se zdravljenje začne z odmerkom 0,1 – 0,2 mg na dan in se nato postopoma povečuje skladno z bolnikovimi individualnimi potrebami.
In patients aged between 12 and 18 years, the published studies showed that the patients had a decrease in the rate of relapse.
Objavljene študije so pokazale, da se je pri bolnikih, starih od 12 do 18 let, stopnja ponovnih napadov zmanjšala.
In patients aged between 15 and 17 years, the starting dose is 2 mg a day, which is gradually increased to the recommended dose of 10 mg once a day.
Pri bolnikih, starih od 15 do 17 let, je začetni odmerek 2 mg na dan, postopoma pa se povečuje na priporočeni 10-miligramski odmerek enkrat na dan.
In patients aged between six and 18
Pri bolnikih, starih od šest do 18 let, ki tehtajo
In patients aged three months to 17 years, the dose depends on body weight.
Pri bolnikih, starih od tri mesece do 17 let, je količina odmerka odvisna od njihove telesne mase.
In patients aged three to 17 years, the dose depends on body weight.
Pri bolnikih, starih od tri do 17 let, je količina odmerka odvisna od njihove telesne mase.
In patients aged ≥ 75 years, both regimens, VcR-CAP as well as R-CHOP, were less tolerated (see section 4.8).
Bolniki, stari ≥ 75 let so oba režima zdravljenja, VcR-CAP in R-CHOP, slabše prenašali (glejte poglavje 4.8).
in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.
ali pri bolnikih, pri katerih bolezen že ustrezno nadzorujemo tako z inhalacijskimi kortikosteroidi kot z dolgodelujočimi agonisti adrenergičnih receptorjev β2.
In patients already adequately controlled with the two active substances, the dose of Rasilez HCT must contain the same doses of aliskiren and hydrochlorothiazide that the patient was taking before.
Pri bolnikih, katerih krvni tlak je že nadzorovan z obema zdravilnima učinkovinama, mora odmerek zdravila Rasilez HCT vsebovati enake odmerke aliskirena in hidroklorotiazida, kot ju je bolnik jemal prej.
in patients already being treated with saxagliptin and metformin as separate tablets;
pri bolnikih, ki se že zdravijo s saksagliptinom in metforminom v obliki ločenih tablet;
In patients already on calcium antagonists or beta blockers at time of dronedarone initiation, an ECG should be performed and the dose should be adjusted if needed.
Bolnikom, ki v času uvedbe dronedarona že dobivajo kalcijeve antagoniste ali blokatorje beta, je treba posneti EKG in jim odmerek prilagoditi, če je treba.
In patients already taking beta blockers at time of dronedarone initiation, an ECG should be performed and the beta blocker dose should be adjusted if needed (see section 4.4).
Bolnikom, ki v času uvedbe dronedarona že dobivajo zaviralce beta, je treba posneti EKG in jim odmerek zaviralca beta prilagoditi, če je potrebno (glejte poglavje 4.4).
In patients at risk for acute renal failure, IVIg products should be administered at the minimum rate of infusion and dose practicable.
Pri bolnikih, ki so ogroženi zaradi možnosti akutne ledvične odpovedi, morate i.v. imunoglobulinske pripravke infundirati z najmanjšo možno hitrostjo in v najmanjšem možnem odmerku.
In patients at risk for thromboembolic adverse reactions, IVIg products should be administered at the minimum rate of infusion and dose practicable.
Pri bolnikih, ki so ogroženi zaradi možnosti tromboemboličnih neželenih učinkov, morate i.v. imunoglobulinske pripravke infundirati z najmanjšo možno hitrostjo in v najmanjšem možnem odmerku.
In patients at risk of bone complications due to spread of cancer to the bone, Xgeva was shown to be effective in delaying the patients’ first skeletal-related event.
Pri bolnikih, pri katerih je bilo zaradi razširitve raka na kosti prisotno tveganje za zaplete, povezane z okostjem, se je zdravilo Xgeva izkazalo za učinkovito pri odložitvi prvega z okostjem povezanega dogodka.
In patients at risk, the use of IVIg products that do not contain these excipients may be considered.
Ig, ki ne vsebujejo teh pomožnih snovi.
In patients at risk, the use of IVIg products that do not contain these excipients may be considered.
Pri bolnikih z dejavniki tveganja bi torej lahko uporabili i.v. imunoglobulinske pripravke, ki ne vsebujejo teh pomožnih snovi.
In patients at steady state, these values are 1.4 ( 0.4) hours and 2.6 ( 0.9) µg/ml, respectively, after a dose ranging from 225 to 550 mg.
Po odmerku v razponu od 225 do 550 mg so pri bolnikih v stanju dinamičnega ravnovesja te vrednosti 1,4 (± 0,4) h in 2,6 (± 0,9) µg/ml.
In patients between 12 months and 17 years of age, the dose depends on body surface area (calculated using the patient’s height and weight).
Pri bolnikih, starih od 12 mesecev do 17 let, je odmerek odvisen od telesne površine (ki se izračuna na podlagi bolnikove višine in telesne mase).
In patients between 12 months and 17 years of age, the dose is calculated using the child’s height and weight.
Pri bolnikih, starih od 12 mesecev do 17 let, se odmerek izračuna na podlagi otrokove višine in telesne mase.
In patients between 3 months and 1 year (n=2), AUC was 5,914 ng·h/mL (CV: 85%) and in patients between 1 and 2 years (n=7), AUC was 3,507 ng·h/mL (CV: 70%).
Pri bolnikih, starih od 3 mesece do 1 leto (n = 2), je bila AUC 5,914 ng h/ml (CV:85 %), pri bolnikih, starih od 1 do 2 leti (n = 7) pa 3,507 ng h/ml (CV: 70 %).
In patients between 3 months and 1 year (n=2), AUC was 5,914 ng·h/mL (CV: 85%) and in patients between 1 and 2 years (n=7), AUC was 3,507 ng·h/mL (CV: 70%).
Pri bolnikih, starih od 3 mesece do 1 leto (n = 2), je bila AUC 5,914 ng h/ml (CV:85%), pri bolnikih, starih od 1 do 2 leti (n = 7) pa 3,507 ng h/ml (CV: 70%).
In patients between 3 months and 2 years, the daily exposure was 7,879 ng·h/mL; AUC was 3,939 ng·h/mL (CV: 72%).
Pri bolnikih, starih od 3 mesece do 2 leti, je bila dnevna izpostavljenost 7,879 ng h/ml, AUC pa 3,939 ng h/ml (CV: 72 %).
In patients between 3 months and 2 years, the daily exposure was 7,879 ng·h/mL; AUC was 3,939 ng·h/mL (CV: 72%).
Pri bolnikih, starih od 3 mesece do 2 leti, je bila dnevna izpostavljenost 7,879 ng h/ml, AUC pa 3,939 ng h/ml (CV: 72%).
In patients co-infected with HCV/HIV, limited efficacy and safety data (N = 25) are available in subjects with CD4 counts less than 200 cells/µl.
Pri bolnikih sočasno okuženi s HCV in HIV, ki imajo število celic CD4 manjše od 200 celic/μl, so na voljo omejeni podatki o učinkovitosti in varnosti zdravila (N = 25).
In patients co-infected with hepatitis B or C virus receiving rilpivirine, the incidence of hepatic enzyme elevation was higher than in patients receiving rilpivirine who were not co-infected.
Pri bolnikih, ki so imeli sočasno okužbo z virusom hepatitisa B in/ali virusom hepatitisa C in so prejemali rilpivirin, je bila pojavnost povečanja koncentracij jetrnih encimov večja, kot pri bolnikih, ki so prejemali rilpivirin, vendar niso imeli sočasne okužbe.
In patients concomitantly taking Lixiana and the following P-gp inhibitors: ciclosporin, dronedarone, erythromycin, or ketoconazole, the recommended dose is 30 mg Lixiana once daily (see section 4.5).
Pri bolnikih, ki sočasno jemljejo zdravilo Lixiana in naslednje inhibitorje P-gp: ciklosporin, dronedaron, eritromicin ali ketokonazol, je priporočeni odmerek 30 mg zdravila Lixiana enkrat na dan (glejte poglavje 4.5).
In patients concomitantly treated with carbamazepine and eslicarbazepine acetate in placebo- controlled studies, the following adverse reactions were observed: diplopia (11.4% of subjects with concomitant carbamazepine, 2.4% of subjects without concomitant carbamazepine), abnormal coordination (6.7% with concomitant carbamazepine, 2.7% without concomitant carbamazepine), and dizziness (30.0% with concomitant carbamazepine, 11.5% without concomitant carbamazepine), see section 4.5.
Pri bolnikih, ki so v študijah, nadzorovanih s placebom, sočasno prejemali karbamazepin in eslikarbazepinacetat, so opazili naslednje neželene učinke : diplopija (11,4 % oseb, ki so sočasno prejemale karbamazepin, 2,4 % oseb, ki niso sočasno prejemali karbamazepina), nenormalna koordinacija (6,7 % pri sočasni uporabi karbamazepina, 2,7 % brez sočasne uporabe karbamazepina), in omotica (30,0 % pri sočasni uporabi karbamazepina, 11.5 % brez sočasne uporabe karbamazepina), glejte poglavje 4.5.
In patients concomitantly treated with carbamazepine and eslicarbazepine acetate in placebo- controlled studies, the following adverse reactions were observed: diplopia (11.4% of subjects with concomitant carbamazepine, 2.4% of subjects without concomitant carbamazepine), abnormal coordination (6.7% with concomitant carbamazepine, 2.7% without concomitant carbamazepine), and dizziness (30.0% with concomitant carbamazepine, 11.5% without concomitant carbamazepine), see section 4.5.
Pri bolnikih, ki so v študijah, nadzorovanih s placebom, sočasno prejemali karbamazepin in eslikarbazepinacetat, so opazili naslednje neželene učinke: diplopija (11,4 % oseb, ki so sočasno prejemale karbamazepin, 2,4 % oseb, ki niso sočasno prejemali karbamazepina), nenormalna koordinacija (6,7 % pri sočasni uporabi karbamazepina, 2,7 % brez sočasne uporabe karbamazepina), in omotica (30,0 % pri sočasni uporabi karbamazepina, 11.5 % brez sočasne uporabe karbamazepina), glejte poglavje 4.5.
In patients considered at high risk treatment with TYSABRI should only be continued if the benefits outweigh the risks.
Pri bolnikih, pri katerih je tveganje veliko, se sme zdravljenje z zdravilom TYSABRI nadaljevati le, če so koristi večje od tveganj.
In patients currently taking
Bolniki, ki jemljejo zdravilo
In patients currently taking
Pri bolnikih z normalnim
In patients defined as INCAT non-responders, muscle strength improved by 5.5 points (95% confidence interval [0.6, 10.2]) as compared to INCAT responders (7.4 points (95% confidence interval [4.0, 11.7])
Pri bolnikih, opredeljenih kot neodzivnimi po INCAT, se je mišična moč izboljšala za 5,5 točke (95-% interval zaupanja [0,6; 10,2]) v primerjavi z bolniki, odzivnimi po INCAT (7,4 točke (95-% interval zaupanja [4,0; 11,7]).
In patients developing PRES, Bortezomib Hospira should be discontinued.
Če se pri bolniku pojavi PRES, je teba zdravljenje z zdravilom Bortezomib Hospira prekiniti.
In patients developing PRES, bortezomib should be discontinued.
Če se pri bolniku pojavi PRES, je teba zdravljenje z bortezomibom prekiniti.
In patients developing PRES, discontinuation of Stivarga, along with control of hypertension and supportive medical management of other symptoms is recommended.
Pri bolnikih, pri katerih se razvije PRES, se priporoča prenehanje zdravljenja z zdravilom Stivarga in hkrati nadzor hipertenzije ter podporna medicinska oskrba drugih simptomov.
In patients developing PRES, VELCADE should be discontinued.
Če se pri bolniku pojavi PRES, je teba zdravljenje z zdravilom VELCADE prekiniti.
In patients either ‘ALK-positive’ or ‘ROS1-positive’, the ALK or ROS1 protein is abnormally active and can promote the growth of cancer cells and the development of new blood vessels that supply them.
Pri bolnikih, ki so ALK-pozitivni ali ROS1-pozitivni, sta ALK in ROS1 beljakovini nenormalno aktivni in lahko spodbudita rast rakavih celic ter nastanek novih krvnih žil, ki te celice oskrbujejo.
In patients experiencing a mild or moderate (CTCAE v 4.0 grades 1 and 2) infusion-related reaction the infusion rate should be reduced for the duration of that infusion.
Bolnikom, ki se jim pojavi blaga ali zmerna (1. in 2. stopnja po CTCAE verzija 4.0) z infundiranjem povezana reakcija, je treba hitrost infundiranja za čas infuzije zmanjšati.
In patients experiencing early diarrhea, therapeutic and prophylactic atropine should be considered unless contraindicated.
Pri bolnikih, ki doživijo zgodnji pojav driske, je treba razmisliti o terapevtskem in profilaktičnem zdravljenju z atropinom, razen če je kontraindicirano.
In patients experiencing this event, it is generally seen after two or three cycles of treatment.
Pri bolnikih, ki imajo ta učinek, se običajno pojavi po dveh ali treh ciklih zdravljenja.
In patients failing therapy with R5-virus only, maraviroc might be considered still active if the maximal percentage inhibition (MPI) value is ≥95% (Phenosense Entry assay).
Pri neuspešno zdravljenih bolnikih, ki so imeli samo R5 virus, lahko maravirok smatramo kot še vedno učinkovit, če je največji delež zaviranja (maximal percentage inhibition , MPI) ≥95% (meritev z metodo PhenoSense Entry).
In patients failing therapy with R5-virus only, maraviroc might be considered still active if the maximal percentage inhibition (MPI) value is ≥95% (Phenosense Entry assay).
Pri neuspešno zdravljenih bolnikih, ki so imeli samo R5 virus, lahko maravirok smatramo kot še vedno učinkovit, če je največji delež zaviranja (maximal percentage inhibition, MPI) ≥95% (meritev z metodo PhenoSense Entry).
In patients followed for up to 16 weeks after discontinuation of treatment at one year, post-treatment ALT elevations were observed more frequently in patients who had received lamivudine than in patients who had received placebo.
Pri bolnikih, ki so jih po prekinitvi zdravljenja nadzirali do 16 tednov, so eno leto po zdravljenju pogosteje opazili povišanje vrednosti ALT pri tistih, ki so dobivali lamivudin, kot pri tistih, ki so dobivali placebo.
In patients followed from month 24 onwards and treated with uncontrolled, open-label Visudyne treatment as needed, long-term extension data suggest that month-24 vision outcomes may be sustained for up to 60 months.
Pri bolnikih, ki so jih od 24. meseca dalje spremljali v odprti nekontrolirani študiji in jih zdravili z zdravilom Visudyne po potrebi, pridobljeni podatki za dolgoročno podaljašnje terapije kažejo, da se izidi vida, doseženi v 24. mesecu, lahko vzdržujejo do 60. meseca.
In patients for whom ciclosporin withdrawal is either unsuccessful or cannot be attempted, the combination of ciclosporin and Rapamune should not be maintained for more than months post-transplantation.
Pri bolnikih, pri katerih je ukinjanje ciklosporina neuspešno ali ga ni mogoče izvesti, lahko kombinirano zdravljenje z zdravilom Rapamune in ciklosporinom traja največ 3 mesece po presaditvi.
In patients for whom monotherapy is inadequate, Ferriprox may be used with deferoxamine at the standard dose (75 mg/kg/day) but should not exceed 100 mg/kg/day.
Pri bolnikih, pri katerih je monoterapija neprimerna, se zdravilo Ferriprox lahko uporablja z deferoksaminom v standardnem odmerku (75 mg/kg/dan), vendar ne sme preseči 100 mg/kg/dan.
In patients given intravenous infusions of 250 mg/m2 rituximab followed by intravenous injections of 15 MBq/kg of [90Y]-radiolabelled Zevalin, the median serum effective half-life of ibritumomab tiuxetan [90Y] was 28 h.
Pri bolnikih, ki so prejeli intravensko infuzijo z 250 mg/m2 rituksimaba, temu pa je sledila intravenska injekcija 15 MBq/kg z [90Y] označenega zdravila Zevalin, je bila srednja efektivna razpolovna doba z ibritumomab tiuksetana [90Y] 28 ur.
in patients in the perioperative liver transplantation period and in neonates up to 4 weeks of age (see section 4.4).
pri bolnikih v perioperativen obdobju presaditve jeter in pri novorojenčkih, starih do 4 tedne (glejte poglavje 4.4).
In patients in whom LIC was not assessed and serum ferritin is ≤2,000 µg/l, dosing should not exceed 10 mg/kg.
≤2.000 µg/l odmerek ne sme preseči 10 mg/kg.
In patients in whom LIC was not assessed and serum ferritin is ≤2,000 µg/l, dosing should not exceed 7 mg/kg.
≤2.000 µg/l odmerek ne sme preseči 7 mg/kg.
in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance
pri bolnikih, ki samo z dieto in telesno vadbo niso zadostno nadzorovani in pri katerih uporaba metformina ni primerna zaradi kontraindikacij ali neprenašanja.
in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.
pri bolnikih, ki samo z dieto in telesno vadbo niso zadostno nadzorovani in pri katerih uporaba metformina ni primerna zaradi kontraindikacij ali neprenašanja.
in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance.
pri bolnikih, pri katerih urejenost glikemije samo z dieto in s telesno aktivnostjo ni zadostna, zdravljenje z metforminom pa zaradi kontraindikacij ali intolerance ni primerno.
in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.
za bolnike z neustrezno urejeno boleznijo ob dieti in telesni aktivnosti, kadar metformin ni primerno zdravilo, ker ga bolniki ne prenašajo ali je kontraindiciran zaradi ledvične okvare.
In patients inadequately controlled on sulphonylurea alone or in combination with metformin, the reduction was 3.5 mmHg with Xultophy and 3.2 mmHg with placebo.
Pri bolnikih z nezadostno urejeno glikemijo pri zdravljenju s sulfonilsečnino, samo ali v kombinaciji z metforminom, je zmanjšanje pri uporabi zdravila Xultophy znašalo 3,5 mmHg, pri uporabi placeba pa 3,2 mmHg.